PROVIDER BULLETIN PROVIDER INFORMATION



January 2, 2023

Medical Policy Updates: Coupe Health and Self-Funded Benefit Plans managed by Blue Cross and Blue Shield of Alabama

Participating providers are invited to submit for consideration scientific, evidence-based information, professional consensus opinions, and other information supported by medical literature relevant to our draft policies for Coupe Health and Self-Funded benefit plans managed by Blue Cross and Blue Shield of Alabama.

The draft policies are available for physician comment for 45 days from the posting date found on the document. At the conclusion of the 45 days, policies will go into effect. Make sure your voice is heard by providing feedback directly to us.

How to Submit Comments on Draft Medical Policies

<u>Complete our medical policy feedback form</u> online at <u>https://mn-policies.exploremyplan.com/portal/web/mn-policies/feedback</u> or send comments and supporting documentation to us by mail or fax:

Birmingham Service Center Attn: Health Management - Medical Policy P.O. Box 10527 Birmingham, AL 35202 Fax: 205-220-0878

Draft Medical Policies

Draft medical policies can be found at Policies & Guidelines (exploremyplan.com)

Policy #	Policy Title
MP-681	Biofeedback
MP-356	Ambulatory Event Monitors and Mobile Cardiac Outpatient Telemetry

Draft Provider-Administered Drug Policies

Draft provider-administered drug policies can be found at <u>Policies & Guidelines (exploremyplan.com)</u> and <u>Policies & Guidelines (exploremyplan.com)</u>

Policy #	Policy Title
PH-403	Immunoglobulin Therapy
VP-0598	Abecma® (idecabtagene vicleucel)
VP-0590	Breyanzi® (lisocabtagene maraleucel)

Bulletin P3-23

Distribution: bluecrossmn.com/providers/forms-and-publications

Blue Cross® and Blue Shield® of Minnesota and Blue Plus® are nonprofit independent licensees of the Blue Cross and Blue Shield Association. L08R04 (12/13)

Policy #	Policy Title
VP-90663	Carvykti™ (ciltacabtagene autoleucel)
VP-0319	Kymriah (tisagenlecleucel)
PH-0579	Oxlumo™ (lumasiran)
VP-0558	Tecartus™ (brexucabtagene autoleucel)
VP-0333	Yescarta™ (axicabtagene ciloleucel)